Centre for Biomedical and Chemical Sciences, School of Science, Auckland University of Technology, Private Bag 92006, Auckland, 1142, New Zealand.
Chem Asian J. 2022 Jun 1;17(11):e202200200. doi: 10.1002/asia.202200200. Epub 2022 Apr 21.
The development of new and effective therapeutics is reliant on the ability to study the underlying mechanisms of potential drug targets in live cells and multicellular systems. A persistent challenge in many drug development programmes is poor selectivity, which can obscure the mechanisms involved and lead to poorly understood modes of action. In efforts to improve our understanding of these complex processes, small molecule inhibitors have been developed in which their OFF/ON therapeutic activity can be toggled using light. Photopharmacology is devoted to using light to modulate drugs. Herein, we highlight the recent progress made towards the development of light-responsive small molecule inhibitors of selected enzymatic targets. Given the size of this field, literature from 2015 onwards has been reviewed.
新型有效治疗方法的开发依赖于在活细胞和多细胞系统中研究潜在药物靶点的基础机制的能力。许多药物开发项目面临的一个持续挑战是选择性差，这可能会掩盖所涉及的机制，并导致对作用模式的理解不足。为了努力提高我们对这些复杂过程的理解，已经开发出了小分子抑制剂，它们的 OFF/ON 治疗活性可以使用光来切换。光药理学致力于使用光来调节药物。本文重点介绍了在开发针对选定酶靶标的光响应小分子抑制剂方面取得的最新进展。鉴于该领域的规模，本文回顾了 2015 年以来的文献。
